Gilead Sciences (GILD) Common Equity (2009 - 2026)

Gilead Sciences (GILD) has reported Common Equity for 18 consecutive years, with $23.5 billion the latest figure, recorded in Q1 2026.

• Common Equity for Q1 2026 came in at $23.5 billion, up 23.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.5 billion (up 23.26% YoY), and the FY2025 annual result was $22.7 billion, up 17.96% from the prior year.
• Common Equity was $23.5 billion for Q1 2026 at Gilead Sciences, up from $22.7 billion in the prior quarter.
• Over five years, Common Equity peaked at $23.5 billion in Q1 2026 and troughed at $17.5 billion in Q1 2024.
• Average Common Equity over 5 years is $20.5 billion, with a median of $20.9 billion recorded in 2023.
• Year-over-year, Common Equity decreased 17.32% in 2024 and advanced 23.26% in 2026.
• Over 5 years, Common Equity stood at $21.2 billion in 2022, then increased by 7.26% to $22.7 billion in 2023, then slipped by 15.4% to $19.2 billion in 2024, then advanced by 17.96% to $22.7 billion in 2025, then advanced by 3.58% to $23.5 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $23.5 billion in Q1 2026, $22.7 billion in Q4 2025, and $21.5 billion in Q3 2025.